Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice

Krzysztof Krzemieniecki,P. Sevelda,F. Erdkamp,M. Smakal,Matthias Schwenkglenks,J. Puertas,A. Trojan,Zsolt Szabo,Kate Bendall,Johanna Mäenpää

Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice

2014

Krzysztof Krzemieniecki
P. Sevelda
F. Erdkamp
M. Smakal
Matthias Schwenkglenks
J. Puertas
A. Trojan
Zsolt Szabo
Kate Bendall
Johanna Mäenpää

Purpose Clinical practice adherence to current guidelines that recommend primary prophylaxis (PP) with granulocyte colony-stimulating factors (G-CSFs) for patients at high (≥20 %) overall risk of febrile neutropenia (FN) was evaluated.

Keywords:

Intensive care medicine
Neutropenia
Granulocyte
Physical therapy
Clinical Practice
Febrile neutropenia
Granulocyte colony-stimulating factor
Medicine
Chemotherapy
Risk assessment
Prospective cohort study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations